KUALA LUMPUR, Nov 4 (Bernama) -- Tessa Therapeutics Ltd (Tessa) announced three abstracts reporting data from clinical trials investigating its autologous CD30.CAR-T therapy (TT11) and allogeneic CD30.CAR EBVST therapy (TT11X) have been accepted for presentation at the 64th American Society of Hematology Annual Meeting (ASH 2022).
In a statement, the clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumours said that the ASH has accepted three abstracts involving Tessa’s autologous and allogeneic CD30.CAR-T therapies, including two oral podium presentations, at its prestigious annual meeting on Dec 10-13 in New Orleans.
“The data being presented at ASH 2022 from the ongoing clinical trials of TT11 and TT11X demonstrate the potential of these therapies to safely and effectively treat CD30 positive lymphomas, including relapsed or refractory classical Hodgkin lymphoma,” said Tessa Therapeutics president and chief executive officer Thomas Willemsen.
Tessa Therapeutics has its global headquarters in Singapore, where it has built a state-of-the-art, commercial cell therapy manufacturing facility.
More details at www.tessacell.com.
-- BERNAMA
Friday 4 November 2022
TESSA THERAPEUTICS TO HIGHLIGHT THREE ABSTRACTS FOR PRESENTATION AT ASH 2022
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment